{
    "name": "bivalirudin",
    "comment": "Rx",
    "other_names": [
        "Angiomax",
        "Angiomax RTU"
    ],
    "classes": [
        "Anticoagulants",
        "Cardiovascular",
        "Anticoagulants",
        "Hematologic"
    ],
    "source": "https://reference.medscape.com/drug/angiomax-angiox-bivalirudin-342137",
    "pregnancy": {
        "common": [
            "There are no data available in pregnant women to inform a drug-associated risk of adverse developmental outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Reproduction studies in rats and rabbits administered subcutaneously doses up to 1.6 times and 3.2 times maximum recommended human dose (MRHD) of 15 mg/kg/day based on body surface area (BSA) during organogenesis, respectively, revealed no evidence of fetal harm"
                ]
            }
        ]
    },
    "lactation": {
        "common": []
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Active major bleeding",
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Bleeding may occur",
                "Use caution in renal impairment",
                "Not for IM administration",
                "Intended for use with aspirin",
                "Hemorrhage may occur at any site; discontinue bivalirudin if unexplained fall in blood pressure or hematocrit occurs",
                "Monitor for signs and symptoms of bleeding; monitor more frequently for bleeding, patients with disease states associated with increased risk of bleeding",
                "An increased risk of thrombus formation, including fatal outcomes, reported with use of bivalirudin in gamma brachytherapy; if decision made to use bivalirudin during brachytherapy procedures, maintain meticulous catheter technique, with frequent aspiration and flushing, paying special attention to minimizing conditions of stasis within catheter or vessels",
                "Bivalirudin affects international normalized ratio (INR); INR measurements made in patients treated with bivalirudin may not be useful for determining appropriate dose of warfarin",
                "Acute stent thrombosis (<4 hr) reported at a greater frequency with bivalirudin compared to heparin treated patients; patients should remain for at least 24 hr in a facility capable of managing ischemic complications and should be carefully monitored following primary PCI for signs and symptoms consistent with myocardial ischemia"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "defibrotide",
            "description": {
                "common": "defibrotide increases effects of bivalirudin by pharmacodynamic synergism. Contraindicated. Coadministration of defibrotide is contraindicated with antithrombotic/fibrinolytic drugs. This does not include use for routine maintenance or reopening of central venous lines."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone, bivalirudin. Other (see comment). Contraindicated. \nComment: Mifepristone may lead to excessive post abortion bleeding in pts. on anticoagulant therapy."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "prothrombin complex concentrate, human",
            "description": {
                "common": "bivalirudin, prothrombin complex concentrate, human. pharmacodynamic synergism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abciximab",
            "description": {
                "common": "bivalirudin, abciximab.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital decreases effects of bivalirudin by increasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anagrelide",
            "description": {
                "common": "bivalirudin, anagrelide.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithrombin alfa",
            "description": {
                "common": "antithrombin alfa and bivalirudin both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithrombin III",
            "description": {
                "common": "antithrombin III and bivalirudin both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apixaban",
            "description": {
                "common": "bivalirudin and apixaban both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "argatroban",
            "description": {
                "common": "argatroban and bivalirudin both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "azithromycin",
            "description": {
                "common": "azithromycin increases effects of bivalirudin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bazedoxifene/conjugated estrogens",
            "description": {
                "common": "bazedoxifene/conjugated estrogens decreases effects of bivalirudin by pharmacodynamic antagonism. Contraindicated. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bemiparin",
            "description": {
                "common": "bemiparin and bivalirudin both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital decreases effects of bivalirudin by increasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital decreases effects of bivalirudin by increasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "caplacizumab",
            "description": {
                "common": "caplacizumab, bivalirudin.\nEither increases effects of the other by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cefamandole",
            "description": {
                "common": "cefamandole increases effects of bivalirudin by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cefazolin",
            "description": {
                "common": "cefazolin increases effects of bivalirudin by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cefdinir",
            "description": {
                "common": "cefdinir increases effects of bivalirudin by anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cefditoren",
            "description": {
                "common": "cefditoren will increase the level or effect of bivalirudin by  anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cefotetan",
            "description": {
                "common": "cefotetan increases effects of bivalirudin by anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cefoxitin",
            "description": {
                "common": "cefoxitin will increase the level or effect of bivalirudin by  anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cefpodoxime",
            "description": {
                "common": "cefpodoxime will increase the level or effect of bivalirudin by  anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ceftriaxone",
            "description": {
                "common": "ceftriaxone will increase the level or effect of bivalirudin by  anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cefuroxime",
            "description": {
                "common": "cefuroxime will increase the level or effect of bivalirudin by  anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cilostazol",
            "description": {
                "common": "bivalirudin, cilostazol.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin increases effects of bivalirudin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clopidogrel",
            "description": {
                "common": "bivalirudin, clopidogrel.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "conjugated estrogens",
            "description": {
                "common": "conjugated estrogens decreases effects of bivalirudin by pharmacodynamic antagonism. Contraindicated. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dalteparin",
            "description": {
                "common": "bivalirudin and dalteparin both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dipyridamole",
            "description": {
                "common": "bivalirudin, dipyridamole.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "edoxaban",
            "description": {
                "common": "edoxaban, bivalirudin.\nEither increases toxicity of the other by anticoagulation. Avoid or Use Alternate Drug. Both drugs have the potential to cause bleeding, monitor closely. Promptly evaluate any signs or symptoms of blood loss. Long-term concomitant treatment with edoxaban and other anticoagulants is not recommended. Short-term coadministration may be needed for patients transitioning to or from edoxaban."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "bivalirudin and enoxaparin both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eptifibatide",
            "description": {
                "common": "bivalirudin, eptifibatide.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "erythromycin base increases effects of bivalirudin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "erythromycin ethylsuccinate increases effects of bivalirudin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "erythromycin lactobionate increases effects of bivalirudin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "erythromycin stearate increases effects of bivalirudin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "estradiol",
            "description": {
                "common": "estradiol decreases effects of bivalirudin by pharmacodynamic antagonism. Contraindicated. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "estrogens conjugated synthetic",
            "description": {
                "common": "estrogens conjugated synthetic decreases effects of bivalirudin by pharmacodynamic antagonism. Contraindicated. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "estropipate",
            "description": {
                "common": "estropipate decreases effects of bivalirudin by pharmacodynamic antagonism. Contraindicated. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "Factor X, human",
            "description": {
                "common": "bivalirudin will decrease the level or effect of Factor X, human by  pharmacodynamic antagonism. Avoid or Use Alternate Drug. Based on the mechanism of action, Factor X is likely to be counteracted by direct and indirect Factor Xa inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fondaparinux",
            "description": {
                "common": "bivalirudin and fondaparinux both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "heparin",
            "description": {
                "common": "bivalirudin and heparin both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levonorgestrel intrauterine",
            "description": {
                "common": "levonorgestrel intrauterine, bivalirudin.\nEither decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levonorgestrel oral",
            "description": {
                "common": "levonorgestrel oral, bivalirudin.\nEither decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levothyroxine",
            "description": {
                "common": "levothyroxine increases effects of bivalirudin by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "liothyronine",
            "description": {
                "common": "liothyronine increases effects of bivalirudin by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mestranol",
            "description": {
                "common": "mestranol decreases effects of bivalirudin by pharmacodynamic antagonism. Contraindicated. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital decreases effects of bivalirudin by increasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenindione",
            "description": {
                "common": "bivalirudin and phenindione both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital decreases effects of bivalirudin by increasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "piperacillin",
            "description": {
                "common": "piperacillin will increase the level or effect of bivalirudin by  anticoagulation. Avoid or Use Alternate Drug. cephalosporins may decrease prothrombin activity"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone decreases effects of bivalirudin by increasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "protamine",
            "description": {
                "common": "bivalirudin and protamine both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quinine",
            "description": {
                "common": "quinine increases effects of bivalirudin by unknown mechanism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "roxithromycin",
            "description": {
                "common": "roxithromycin increases effects of bivalirudin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital decreases effects of bivalirudin by increasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sulfadiazine",
            "description": {
                "common": "sulfadiazine increases effects of bivalirudin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sulfamethoxazole",
            "description": {
                "common": "sulfamethoxazole increases effects of bivalirudin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sulfisoxazole",
            "description": {
                "common": "sulfisoxazole increases effects of bivalirudin by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thyroid desiccated",
            "description": {
                "common": "thyroid desiccated increases effects of bivalirudin by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tibolone",
            "description": {
                "common": "tibolone increases effects of bivalirudin by pharmacodynamic synergism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ticlopidine",
            "description": {
                "common": "bivalirudin, ticlopidine.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tirofiban",
            "description": {
                "common": "bivalirudin, tirofiban.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Enhanced risk of hemorrhage."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "warfarin",
            "description": {
                "common": "bivalirudin increases effects of warfarin by anticoagulation. Avoid or Use Alternate Drug. Avoid combined use once INR is established in the desired therapeutic range."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acalabrutinib increases effects of bivalirudin by anticoagulation. Use Caution/Monitor. Coadministration of acalabrutinib with antiplatelets or anticoagulants may further increase risk of hemorrhage. Monitor for signs of bleeding and consider the benefit-risk of withholding acalabrutinib for 3-7 days presurgery and postsurgery depending upon the type of surgery and the risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aceclofenac",
            "description": {
                "common": "bivalirudin and aceclofenac both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acemetacin",
            "description": {
                "common": "bivalirudin and acemetacin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "agrimony",
            "description": {
                "common": "bivalirudin and agrimony both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfalfa",
            "description": {
                "common": "bivalirudin and alfalfa both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alteplase",
            "description": {
                "common": "bivalirudin and alteplase both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "American ginseng",
            "description": {
                "common": "bivalirudin and American ginseng both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "anamu",
            "description": {
                "common": "bivalirudin and anamu both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "bivalirudin and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "bivalirudin and aspirin rectal both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "aspirin/citric acid/sodium bicarbonate, bivalirudin.\nEither increases toxicity of the other by anticoagulation. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azapropazone",
            "description": {
                "common": "azapropazone increases effects of bivalirudin by plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azathioprine",
            "description": {
                "common": "azathioprine decreases effects of bivalirudin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azficel-T",
            "description": {
                "common": "azficel-T, bivalirudin. Other (see comment). Use Caution/Monitor. \nComment: Coadministration with anticoagulants or antiplatelets may increase bruising or bleeding at biopsy and/or injection sites; concomitant use not recommended. Decisions regarding continued use or cessation of anticoagulants or antiplatelets should be made by a physician."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betrixaban",
            "description": {
                "common": "bivalirudin, betrixaban.\nEither increases levels of the other by anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "budesonide",
            "description": {
                "common": "budesonide, bivalirudin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "capecitabine",
            "description": {
                "common": "capecitabine increases effects of bivalirudin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine decreases levels of bivalirudin by increasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celecoxib",
            "description": {
                "common": "bivalirudin and celecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chitosan",
            "description": {
                "common": "chitosan increases effects of bivalirudin by Other (see comment). Use Caution/Monitor. \nComment: Chitosan can decrease GI absorption of vitamin K, enhancing anticoagulant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "bivalirudin and choline magnesium trisalicylate both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cinnamon",
            "description": {
                "common": "bivalirudin and cinnamon both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "citalopram increases effects of bivalirudin by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "collagenase clostridium histolyticum",
            "description": {
                "common": "bivalirudin increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conjugated estrogens, vaginal",
            "description": {
                "common": "conjugated estrogens, vaginal decreases effects of bivalirudin by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cordyceps",
            "description": {
                "common": "bivalirudin and cordyceps both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cornsilk",
            "description": {
                "common": "cornsilk decreases effects of bivalirudin by pharmacodynamic antagonism. Use Caution/Monitor. Cornsilk contains vitamin K; consume a consistent amount daily."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cortisone",
            "description": {
                "common": "cortisone, bivalirudin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide increases effects of bivalirudin by unknown mechanism. Use Caution/Monitor. Additive risk of bleeding may be seen in thrombocytopenic patients receiving antineoplastic agents in combination with anticoagulants such as bivalirudin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabigatran",
            "description": {
                "common": "bivalirudin and dabigatran both increase  anticoagulation. Use Caution/Monitor. Caution is advised, both drugs have the potential to cause bleeding. Concomitant use may increase risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "danshen",
            "description": {
                "common": "bivalirudin and danshen both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deferasirox",
            "description": {
                "common": "deferasirox, bivalirudin. Other (see comment). Use Caution/Monitor. \nComment: Gastric ulceration and GI bleeding have been reported in patients taking deferasirox, use caution when coadministering with other drugs known to increase the risk of peptic ulcers or gastric hemorrhage including anticoagulants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deflazacort",
            "description": {
                "common": "deflazacort, bivalirudin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "devil's claw",
            "description": {
                "common": "bivalirudin and devil's claw both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone, bivalirudin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diclofenac",
            "description": {
                "common": "bivalirudin and diclofenac both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diflunisal",
            "description": {
                "common": "bivalirudin and diflunisal both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dong quai",
            "description": {
                "common": "bivalirudin and dong quai both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epoprostenol",
            "description": {
                "common": "bivalirudin and epoprostenol both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethanol",
            "description": {
                "common": "ethanol increases effects of bivalirudin by unknown mechanism. Use Caution/Monitor. Acute EtOH intoxication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethotoin",
            "description": {
                "common": "bivalirudin increases levels of ethotoin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etodolac",
            "description": {
                "common": "bivalirudin and etodolac both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenbufen",
            "description": {
                "common": "bivalirudin and fenbufen both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fennel",
            "description": {
                "common": "bivalirudin and fennel both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenoprofen",
            "description": {
                "common": "bivalirudin and fenoprofen both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "feverfew",
            "description": {
                "common": "bivalirudin and feverfew both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fish oil",
            "description": {
                "common": "fish oil, bivalirudin. Other (see comment). Use Caution/Monitor. \nComment: Patients taking fish oil and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fish oil triglycerides",
            "description": {
                "common": "fish oil triglycerides will increase the level or effect of bivalirudin by  anticoagulation. Use Caution/Monitor. Prolonged bleeding reported in patients taking antiplatelet agents or anticoagulants and oral omega-3 fatty acids. Periodically monitor bleeding time in patients receiving fish oil triglycerides and concomitant antiplatelet agents or anticoagulants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "fludrocortisone, bivalirudin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluorouracil",
            "description": {
                "common": "fluorouracil increases effects of bivalirudin by unspecified interaction mechanism. Use Caution/Monitor. Due to the thrombocytopenic effects of fluorouracil, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurbiprofen",
            "description": {
                "common": "bivalirudin and flurbiprofen both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "forskolin",
            "description": {
                "common": "bivalirudin and forskolin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "bivalirudin increases levels of fosphenytoin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "garlic",
            "description": {
                "common": "bivalirudin and garlic both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemcitabine",
            "description": {
                "common": "gemcitabine increases effects of bivalirudin by unspecified interaction mechanism. Use Caution/Monitor. Due to the thrombocytopenic effects of gemcitabine, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ginger",
            "description": {
                "common": "bivalirudin and ginger both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ginkgo biloba",
            "description": {
                "common": "bivalirudin and ginkgo biloba both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glucagon intranasal",
            "description": {
                "common": "glucagon intranasal increases effects of bivalirudin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "green tea",
            "description": {
                "common": "green tea, bivalirudin. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of bleeding, caution is advised."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hemin",
            "description": {
                "common": "bivalirudin, hemin.\nEither increases effects of the other by anticoagulation. Use Caution/Monitor. Hemin degradation product (ie, hematin) may produce coagulopathy (eg, thrombocytopenia, platelet degranulation) and cause mild anticoagulant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "horse chestnut seed",
            "description": {
                "common": "bivalirudin and horse chestnut seed both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "hydrocortisone, bivalirudin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibrutinib",
            "description": {
                "common": "ibrutinib will increase the level or effect of bivalirudin by  anticoagulation. Use Caution/Monitor. Ibrutinib may increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies and monitor for signs of bleeding. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "bivalirudin and ibuprofen both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen IV",
            "description": {
                "common": "bivalirudin and ibuprofen IV both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "icosapent",
            "description": {
                "common": "icosapent, bivalirudin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imatinib",
            "description": {
                "common": "imatinib, bivalirudin.\nEither increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Imatinib may cause thrombocytopenia; bleeding risk increased when imatinib is coadministered with anticoagulants, NSAIDs, platelet inhibitors, and thrombolytic agents; patients requiring anticoagulation while on imatinib should receive LMWH or unfractionated heparin instead of warfarin because of multiple interaction mechanisms of imatinib with warfarin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indomethacin",
            "description": {
                "common": "bivalirudin and indomethacin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iodine (radioactive)",
            "description": {
                "common": "iodine (radioactive) decreases effects of bivalirudin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoprofen",
            "description": {
                "common": "bivalirudin and ketoprofen both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac",
            "description": {
                "common": "bivalirudin and ketorolac both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac intranasal",
            "description": {
                "common": "bivalirudin and ketorolac intranasal both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofepramine",
            "description": {
                "common": "lofepramine increases levels of bivalirudin by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lornoxicam",
            "description": {
                "common": "bivalirudin and lornoxicam both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meclofenamate",
            "description": {
                "common": "bivalirudin and meclofenamate both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mefenamic acid",
            "description": {
                "common": "bivalirudin and mefenamic acid both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "melatonin",
            "description": {
                "common": "melatonin increases effects of bivalirudin by anticoagulation. Use Caution/Monitor. Melatonin may decrease prothrombin time."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meloxicam",
            "description": {
                "common": "bivalirudin and meloxicam both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methimazole",
            "description": {
                "common": "methimazole decreases effects of bivalirudin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "methylprednisolone, bivalirudin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mistletoe",
            "description": {
                "common": "bivalirudin increases and mistletoe decreases anticoagulation. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nabumetone",
            "description": {
                "common": "bivalirudin and nabumetone both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naproxen",
            "description": {
                "common": "bivalirudin and naproxen both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nettle",
            "description": {
                "common": "bivalirudin increases and nettle decreases anticoagulation. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nintedanib",
            "description": {
                "common": "nintedanib increases effects of bivalirudin by anticoagulation. Use Caution/Monitor. Nintedanib is a VEGFR inhibitor, and may increase the risk of bleeding; monitor patients on full anticoagulation therapy; monitor closely for bleeding and adjust therapy as needed ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omega 3 carboxylic acids",
            "description": {
                "common": "omega 3 carboxylic acids, bivalirudin. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3 acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omega 3 fatty acids",
            "description": {
                "common": "omega 3 fatty acids, bivalirudin. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaprozin",
            "description": {
                "common": "bivalirudin and oxaprozin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "panax ginseng",
            "description": {
                "common": "bivalirudin and panax ginseng both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "parecoxib",
            "description": {
                "common": "bivalirudin and parecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pau d'arco",
            "description": {
                "common": "bivalirudin and pau d'arco both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pegaspargase",
            "description": {
                "common": "pegaspargase increases effects of bivalirudin by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of bleeding events."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "bivalirudin increases levels of phenytoin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phytoestrogens",
            "description": {
                "common": "bivalirudin and phytoestrogens both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "piroxicam",
            "description": {
                "common": "bivalirudin and piroxicam both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "porfimer",
            "description": {
                "common": "bivalirudin decreases effects of porfimer by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prasugrel",
            "description": {
                "common": "bivalirudin, prasugrel.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced risk of hemorrhage."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisolone",
            "description": {
                "common": "prednisolone, bivalirudin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisone",
            "description": {
                "common": "prednisone, bivalirudin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propafenone",
            "description": {
                "common": "propafenone increases effects of bivalirudin by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propylthiouracil",
            "description": {
                "common": "propylthiouracil decreases effects of bivalirudin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "reishi",
            "description": {
                "common": "bivalirudin and reishi both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "reteplase",
            "description": {
                "common": "bivalirudin and reteplase both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin decreases levels of bivalirudin by increasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rivaroxaban",
            "description": {
                "common": "rivaroxaban, bivalirudin.\nEither increases effects of the other by anticoagulation. Use Caution/Monitor. Avoid concurrent use of rivaroxaban with other anticoagulants due to increased bleeding risk other than during therapeutic transition periods where patients should be observed closely. Monitor for signs/symptoms of blood loss."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salicylates (non-asa)",
            "description": {
                "common": "bivalirudin and salicylates (non-asa) both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salsalate",
            "description": {
                "common": "bivalirudin and salsalate both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saw palmetto",
            "description": {
                "common": "saw palmetto increases toxicity of bivalirudin by unspecified interaction mechanism. Use Caution/Monitor. May increase risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "Siberian ginseng",
            "description": {
                "common": "bivalirudin and Siberian ginseng both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfasalazine",
            "description": {
                "common": "bivalirudin and sulfasalazine both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulindac",
            "description": {
                "common": "bivalirudin and sulindac both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenecteplase",
            "description": {
                "common": "bivalirudin and tenecteplase both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ticagrelor",
            "description": {
                "common": "ticagrelor, bivalirudin.\nEither increases effects of the other by anticoagulation. Use Caution/Monitor. Increased risk of bleeding during concomitant use of medications that increase potential for bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir increases effects of bivalirudin by pharmacodynamic synergism. Use Caution/Monitor. Tipranavir has mild antiplatelet activity that may incr bleeding risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolfenamic acid",
            "description": {
                "common": "bivalirudin and tolfenamic acid both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolmetin",
            "description": {
                "common": "bivalirudin and tolmetin both increase  anticoagulation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "triamcinolone acetonide injectable suspension, bivalirudin. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triclofos",
            "description": {
                "common": "triclofos increases effects of bivalirudin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vorapaxar",
            "description": {
                "common": "bivalirudin, vorapaxar.\nEither increases effects of the other by anticoagulation. Use Caution/Monitor. Coadministration of anticoagulants, antiplatelets, or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vortioxetine",
            "description": {
                "common": "vortioxetine and bivalirudin both increase  anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zanubrutinib",
            "description": {
                "common": "bivalirudin, zanubrutinib.\nEither increases effects of the other by anticoagulation. Modify Therapy/Monitor Closely. Zanubrutinib-induced cytopenias increases risk of hemorrhage. Coadministration of zanubritinib with antiplatelets or anticoagulants may further increase this risk."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetaminophen",
            "description": {
                "common": "acetaminophen increases effects of bivalirudin by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetaminophen IV",
            "description": {
                "common": "acetaminophen IV increases effects of bivalirudin by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetaminophen rectal",
            "description": {
                "common": "acetaminophen rectal increases effects of bivalirudin by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alprostadil intracavernous/urethral",
            "description": {
                "common": "alprostadil intracavernous/urethral increases effects of bivalirudin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ceftaroline",
            "description": {
                "common": "ceftaroline increases effects of bivalirudin by Other (see comment). Minor/Significance Unknown. \nComment: Cephalosporins with a methylthiotetrazole (MTT) side ring (eg, cefotetan, cefoperazone) are more frequently associated with hypoprothrombinemic activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorella",
            "description": {
                "common": "chlorella decreases effects of bivalirudin by pharmacodynamic antagonism. Minor/Significance Unknown. Theoretical, due to vitamin K content."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "demeclocycline",
            "description": {
                "common": "demeclocycline increases effects of bivalirudin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexmethylphenidate",
            "description": {
                "common": "dexmethylphenidate increases effects of bivalirudin by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "doxycycline",
            "description": {
                "common": "doxycycline increases effects of bivalirudin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glyburide",
            "description": {
                "common": "glyburide increases effects of bivalirudin by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mineral oil",
            "description": {
                "common": "mineral oil decreases levels of bivalirudin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "minocycline",
            "description": {
                "common": "minocycline increases effects of bivalirudin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxytetracycline",
            "description": {
                "common": "oxytetracycline increases effects of bivalirudin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "quinidine",
            "description": {
                "common": "quinidine increases effects of bivalirudin by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "serdexmethylphenidate/dexmethylphenidate",
            "description": {
                "common": "serdexmethylphenidate/dexmethylphenidate increases effects of bivalirudin by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tetracycline",
            "description": {
                "common": "tetracycline increases effects of bivalirudin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "verteporfin",
            "description": {
                "common": "bivalirudin decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vitamin E",
            "description": {
                "common": "vitamin E, bivalirudin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Vitamin E at RDA does not change INR in pts. on chronic warfarin therapy; megadoses (~10x RDA) may enhance anticoagulant effects in vitamin K deficient pts."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Back pain",
            "percent": "42"
        },
        {
            "name": "General pain",
            "percent": "15"
        },
        {
            "name": "Nausea",
            "percent": "15"
        },
        {
            "name": "Hemorrhage",
            "percent": "13.6"
        },
        {
            "name": "minor",
            "percent": "12"
        },
        {
            "name": "Headache",
            "percent": "12"
        },
        {
            "name": "Hypotension",
            "percent": "8"
        },
        {
            "name": "Injection site pain",
            "percent": "7"
        },
        {
            "name": "Insomnia",
            "percent": "6"
        },
        {
            "name": "Pelvic pain",
            "percent": "6"
        },
        {
            "name": "Hypertension",
            "percent": "6"
        },
        {
            "name": "Anxiety",
            "percent": "6"
        },
        {
            "name": "Vomiting",
            "percent": "5"
        },
        {
            "name": "Bradycardia",
            "percent": "5"
        },
        {
            "name": "Dyspepsia",
            "percent": "5"
        },
        {
            "name": "Abdominal pain",
            "percent": "5"
        },
        {
            "name": "Fever",
            "percent": "5"
        },
        {
            "name": "Nervousness",
            "percent": "4"
        },
        {
            "name": "Urinary retention",
            "percent": "2.3"
        },
        {
            "name": "Hemorrhage",
            "percent": "3"
        },
        {
            "name": "major",
            "percent": "1.9"
        },
        {
            "name": "g",
            "percent": "1.3"
        },
        {
            "name": "dL fall in Hgb",
            "percent": "1.3"
        },
        {
            "name": "TIMI minor bleeding",
            "percent": null
        },
        {
            "name": "RBC transfusions",
            "percent": null
        },
        {
            "name": "Pulmonary hemorrhage",
            "percent": null
        },
        {
            "name": "Cardiac tamponade",
            "percent": null
        },
        {
            "name": "INR increased",
            "percent": null
        }
    ]
}